Advertisement

Pharmacy World and Science

, Volume 17, Issue 2, pp 25–30 | Cite as

Concise overview of the clinical pharmacokinetics of dideoxynucleoside antiretroviral agents

  • David M. Burger
  • Pieter L. Meenhorst
  • Jos H. Beijnen
Reviews

Abstract

In this paper aspects of the clinical pharmacokinetics of the antiretroviral agents zidovudine, didanosine and zalcitabine are reviewed. Special attention is paid to possibly altered pharmacokinetics in special circumstances, such as hepatic and renal dysfunction, pregnancy, stage of disease,etc. The dideoxynucleoside antiretroviral agents have some clinical pharmacokinetic properties in common (rapid absorption and elimination), but substantial differences exist in their degree of absorption, metabolism and penetration into the cerebrospinal fluid. All agents display wide interpatient variability in pharmacokinetic parameters. The relevance of therapeutic drug monitoring of antiretroviral agents is also discussed.

Keywords

Didanosine Pharmacokinetics Therapeutic drug monitoring Zalcitabine Zidovudine 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Hirsch MS, D'Aquila RT. Therapy for human immunodeficiency virus infection. N Engl J Med 1993;328(23):1686–95.Google Scholar
  2. 2.
    Kahn JO, Lagakos SW, Richman DD, Cross A, Pettinelli C, Liou S-H, et al.. A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. N Engl J Med 1992;327(9):581–7.Google Scholar
  3. 3.
    Spruance SL, Pavia AT, Peterson D, Berry A, Pollard R, Patterson TF, et al.. Didanosine compared with continuation of zidovudine in HIV-infected patients with signs of clinical deterioration while receiving zidovudine. A randomized, double-blind clinical trial. Ann Intern Med 1994;120(5):360–8.Google Scholar
  4. 4.
    Fischl MA, Olson RM, Follansbee SE, Lalezari JP, Henry DH, Frame PT, et al.. Zalcitabine compared with zidovudine in patients with advanced HIV-1 infection who received previous zidovudine therapy. Ann Intern Med 1993;118(10):762–9.Google Scholar
  5. 5.
    Collier AC, Coombs RW, Fischl MA, Skolnik PR, Northfelt D, Boutin P, et al.. Combination therapy with zidovudine and didanosine compared with zidovudine alone in HIV-1 infection. Ann Intern Med 1993;119(8):786–93.Google Scholar
  6. 6.
    Meng T-C, Fischl MA, Boota AM, Spector SA, Bennett D, Bassiakos Y, et al.. Combination therapy with zidovudine and dideoxycytidine in patients with advanced human immunodeficiency virus infection. A phase I/II study. Ann Intern Med 1992;116(1):13–20.Google Scholar
  7. 7.
    Wilde MI, Langtry HD. Zidovudine. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs 1993;46(3):515–78.Google Scholar
  8. 8.
    Faulds D, Brogden RN. Didanosine. A review of its antiviral activity, pharmacokinetic properties and therapeutic potential in human immunodeficiency virus infection. Drugs 1992;44(1):94–116.Google Scholar
  9. 9.
    Whittington R, Brogden RN. Zalcitabine. A review of its pharmacology and clinical potential in acquired immunodeficiency syndrome (AIDS). Drugs 1992;44(4):656–83.Google Scholar
  10. 10.
    Morse GD, Shelton MJ, O'Donnel AM. Comparative pharmacokinetics of antiviral nucleoside analogues. Clin Pharmacokin 1993;24(2):101–23.Google Scholar
  11. 11.
    Shelton MJ, O'Donnel AM, Morse GD. Didanosine. Ann Pharmacother 1992;26(5):660–70.Google Scholar
  12. 12.
    Shelton MJ, O'Donnel AM, Morse GD. Zalcitabine. Ann Pharmacother 1993;27(4):480–9.Google Scholar
  13. 13.
    Unadkat JD, Collier AC, Crosby SS, Cummings D, Opheim KE, Corey L. Pharmacokinetics of oral zidovudine (azidothymidine) in patients with AIDS when administered with and without a high-fat meal. AIDS 1990;4(3):229–32.Google Scholar
  14. 14.
    Lotterer E, Ruhnke M, Trautmann M, Beyer R, Bauer FE. Decreased and variable systemic availability of zidovudine in patients with AIDS if administered with a meal. Eur J Clin Pharmacol 1991;40:305–8.Google Scholar
  15. 15.
    Sahai J, Gallicano K, Garber C, McGilveray I, Hawley-Foss N, Turgeon N, et al. The effect of a protein meal on zidovudine pharmacokinetics in HIV-infected patients. Br J Clin Pharmacol 1992;33:657–60.Google Scholar
  16. 16.
    Ruhnke M, Bauer FE, Seifert M, Trautmann M, Hille H, Koeppe P. Effects of standard breakfast on pharmacokinetics of oral zidovudine in patients with AIDS. Antimicrob Agents Chemother 1993;37(10):2153–8.Google Scholar
  17. 17.
    MacNab KA, Gill MJ, Sutherland LR, De Boer Visser N, Church D. Erratic bioavailability in HIV seropositive patients. J Antimicrob Chemother 1993;31:421–8.Google Scholar
  18. 18.
    Gitterman SR, Drusano GL, Egorin MJ, Standiford HC, and the Veterans Administration Cooperative Studies Group. Population pharmacokinetics of zidovudine. Clin Pharmacol Ther 1990;48(2):161–7.Google Scholar
  19. 19.
    Anderson DJ, O'Brien TR, Politch JA, Martinez A, Seage III GR, Padian N, et al.. Effects of disease stage and zidovudine therapy on the detection of human immunodeficiency virus type 1 in semen. JAMA 1992;267(20):2769–74.Google Scholar
  20. 20.
    Rolinski B, Wintergerst U, Matuschke A, Füessl H, Goebel FD, Roscher AA, et al.. Evaluation of saliva as specimen for monitoring zidovudine therapy in HIV-infected patients. AIDS 1990;5(7):885–8.Google Scholar
  21. 21.
    Watts DH, Brown ZA, Tartaglione T, Burchett SK, Opheim K, Coombs R, et al.. Pharmacokinetic disposition of ZDV during pregnancy. J Infect Dis 1991;163(2):226–32.Google Scholar
  22. 22.
    O'Sullivan MJ, Boyer PJJ, Scott GB, Parks WP, Weller S, Blum MR, et al.. The pharmacokinetics and safety of zidovudine in the third trimester of pregnancy for women infected with human immunodeficiency virus and their infants: phase 1 acquired immunodeficiency syndrome clinical trials group study (protocol 082). Am J Obstet Gynecol 1993;168(5):1510–6.Google Scholar
  23. 23.
    Sperling RS, Roboz J, Dische R, Silides D, Holzman I, Jew E. Zidovudine pharmacokinetics during pregnancy. Am J Perinatol 1992;9(4):247–9.Google Scholar
  24. 24.
    Burger DM, Kraaijeveld CL, Meenhorst PL, Mulder JW, Koks CHW, Bult A, et al.. Penetration of zidovudine into the cerebrospinal fluid of patients infected with HIV. AIDS 1993;7(12):1581–7.Google Scholar
  25. 25.
    Howe JL, Back DJ, Colbert J. Extrahepatic metabolism of zidovudine. Br J Clin Pharmacol 1992;33:190–2.Google Scholar
  26. 26.
    Stagg MP, Cretton EM, Kidd L, Diasio RB, Sommadossi J-P. Clinical pharmacokinetics of 3′-azido-3′-deoxythymidine (zidovudine) and catabolites with formation of a toxic catabolite, 3′-amino-3′-deoxythymidine. Clin Pharmacol Ther 1992;51(6):668–76.Google Scholar
  27. 27.
    Taburet A-M, Naveau S, Zorza G, Colin J-N, Delfraissy J-F, Chaput J-C, et al.. Pharmacokinetics of zidovudine in patients with liver cirrhosis. Clin Pharmacol Ther 1990;47(6):731–9.Google Scholar
  28. 28.
    Fletcher CV, Rhame FS, Beatty CC, Simpson M, Balfour HH Jr. Comparative pharmacokinetics of zidovudine in healthy volunteers and in patients with AIDS with and without hepatic disease. Pharmacotherapy 1992;12(6):429–34.Google Scholar
  29. 29.
    Singlas E, Pioger J-C, Taburet A-M, Colin J-N, Fillastre J-P. Zidovudine disposition in patients with severe renal impairment: influence of hemodialysis. Clin Pharmacol Ther 1989;46(2):190–7.Google Scholar
  30. 30.
    Pachon J, Cisneros JM, Castillo JR, Garcia-Pesqura F, Canas E, Viciana P. Pharmacokinetics of zidovudine in end-stage renal disease: influence of haemodialysis. AIDS 1992;6(8):827–30.Google Scholar
  31. 31.
    Burger DM, Meenhorst PL, Mulder JW, Koks CHW, Bult A, Beijnen JH. Pharmacokinetics of zidovudine and metabolites in a patient with HIV-associated nephropathy and severe renal impairment. Drug Invest 1994;7(5):282–7.Google Scholar
  32. 32.
    Lee BL, Wong D, Benowitz NL, Sullam PM. Altered pattern of drug metabolism in patients with acquired immunodeficiency syndrome. Clin Pharmacol Ther 1993;53(5):529–35.Google Scholar
  33. 33.
    Boucher FD, Modlin JF, Weller S, Ruff A, Mirochnick M, Pelton S, et al.. Phase I evaluation of zidovudine administered to infants exposed at birth to the human immunodeficiency virus. J Pediatr 1993;122(1):137–44.Google Scholar
  34. 34.
    Kroemer HK, Klotz U. Glucuronidation of drugs. A re-evaluation of the pharmacological significance of the conjugates and modulating factors. Clin Pharmacokin 1992;23(4):292–310.Google Scholar
  35. 35.
    Anderson BD, Wygant MB, Xiang T-X, Waugh WA, Stella VJ. Preformulation solubility and kinetic studies of 2′,3′-dideoxypurine nucleosides: potential anti-AIDS agents. Int J Pharm 1988,45(1):27–37.Google Scholar
  36. 36.
    Bekers O, Beijnen JH, Klein Tank MJT, Burger DM, Meenhorst PL, Lombarts AJPF, et al.. 2′,3′-Dideoxyinosine (ddl): its chemical stability and cyclodextrin complexation in aqueous media. J Pharm Biomed Anal 1993;11 (6):489–93.Google Scholar
  37. 37.
    Chyi Shyu W, Knupp CA, Pittman KA, Dunkle L, Barbhaiya RH. Food-induced reduction in bioavailability of didanosine. Clin Pharmacol Ther 1991;50(5):503–7.Google Scholar
  38. 38.
    Pons JC, Boubon MC, Taburet AM, Singlas E, Chambrin V, Frydman R, et al.. Fetoplacental passage of 2′,3′-dideoxyinosine. Lancet 1991;337:732.Google Scholar
  39. 39.
    Dancis J, Lee JD, Mendoza S, Liebes L. Transfer and metabolism of dideoxyinosine by the perfused human placenta. J Acquir Immune Defic Syndr 1993;6(1):2–6.Google Scholar
  40. 40.
    Barry M, Back D, Ormesher S, Beeching N, Nye F. Metabolism of didanosine (ddl) by erythrocytes: pharmacokinetic implications. Br J Clin Pharmacol 1993;36:87–8.Google Scholar
  41. 41.
    Singlas E, Taburet AM, Borsa Lebas F, Parent de Curzon O, Sobel A, Chaveau P, et al.. Didanosine pharmacokinetics in patients with normal and impaired renal function: influence of hemodialysis. Antimicrob Agents Chemother 1992;36(7):1519–24.Google Scholar
  42. 42.
    Balis FM, Pizzo PA, Butler KM, Hawkins ME, Brouwers P, Husson RN, et al.. Clinical pharmacology 2′,3′-dideoxyinosine in human immunodeficiency virus-infected children. J Infect Dis 1992;165(1):99–104.Google Scholar
  43. 43.
    Kelley JA, Litterst CL, Roth JS, Vistica DT, Poplack DG, Cooney DA, et al.. The disposition and metabolism of 2′,3′-dideoxycytidine, anin vitro inhibitor of human T-lymphotropic virus type III infectivity, in mice and monkeys. Drug Metab Dispos 1987;15(5):595–601.Google Scholar
  44. 44.
    Massarella JW, Mould DR, Patel I. Influence of body weight on the kinetics of dideoxycytidine [abstract]. Clin Pharmacol Ther 1993;53(2):184 Abstr PII-55.Google Scholar
  45. 45.
    Balis FM, Pizzo PA, Murphy RF, Eddy J, Jarosinski PF, Falloon J, et al.. The pharmacokinetics of zidovudine administered by continuous infusion in children. Ann Intern Med 1989; 110(4):279–85.Google Scholar
  46. 46.
    Vocks-Hauc M, Wintergerst U, Rolinski B, Goll M, Langhof M, Belohradsky B-H, et al.. Side-effects of zidovudine in correlation to plasma levels in children [abstract]. AIDS 1992;6(Suppl 1):S37 Abstr P86.Google Scholar
  47. 47.
    Drusano GL, Yuen GJ, Lambert JS, Seidlin M, Dolin R, Valentine FT. Relationship between dideoxyinosine exposure, CD4 counts, and p24 antigen levels in human immunodeficiency virus infection. Ann Intern Med 1992;116(7):562–6.Google Scholar
  48. 48.
    Beltangady M, Knupp CA, Gustafson N, Barbhaiya RH, Dolin R, Seidlin M, et al.. Relation between plasma concentrations of didanosine and markers of antiviral efficacy in adults with AIDS or AIDS-related complex. Clin Infect Dis 1993;16 Suppl 1:S26–31.Google Scholar
  49. 49.
    Grasela TH, Walawander CA, Beltangady M, Knupp CA. Risk factors for pancreatitis in phase 1 trials of didanosine [abstract]. Clin Pharmacol Ther 1992;51(2):126 Abstr PI-21.Google Scholar
  50. 50.
    Stretcher BN, Pesce AJ, Murray JA, Hurtubise PE, Vine WH, Frame PT. Concentrations of phosphorylated zidovudine (ZDV) in patient leukocytes do not correlate with ZDV dose or plasma concentration. Ther Drug Monitor 1991;13(4): 325–31.Google Scholar
  51. 51.
    Stretcher BN, Pesce AJ, Hurtubise PE, Frame PT. Pharmacokinetics of zidovudine phosphorylation in patients infected with the human immunodeficiency virus. Ther Drug Monitor 1992;14(4):281–5.Google Scholar
  52. 52.
    Kuster H, Vogt M, Joos B, Nadai V, Lüthy R. A method for the quantification of intracellular zidovudine nucleotides. J Infect Dis 1991;164(4):773–6.Google Scholar
  53. 53.
    Slusher JT, Kuwahara SK, Hamzeh FM, Lewis LD, Kornhauser DM, Lietman PS. Intracellular zidovudine (ZDV) and ZDV phosphates as measured by a validated combined highpressure liquid chromatography-radioimmunoassay procedure. Antimicrob Agents Chemother 1992;36(11):2473–7.Google Scholar

Copyright information

© Royal Dutch Association for Advancement of Pharmacy 1995

Authors and Affiliations

  • David M. Burger
    • 1
  • Pieter L. Meenhorst
    • 2
  • Jos H. Beijnen
    • 3
  1. 1.Department of PharmacySlotervaart HospitalEC Amsterdamthe Netherlands
  2. 2.Department of Internal MedicineSlotervaart HospitalAmsterdamthe Netherlands
  3. 3.Department of PharmacySlotervaart HospitalAmsterdamthe Netherlands

Personalised recommendations